Complete Story


ASAM releases practice guideline for the use of medications involving opioid use

Contact: Beth Haynes, 301-547-4123

CHEVY CHASE, MD, June 2, 2015 – ASAM announces the release of its National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use (Practice Guideline). The Practice Guideline will assist clinicians prescribing pharmacotherapies to patients with addiction related to opioid use. It addresses knowledge gaps about the benefits of treatment medications and their role in recovery, while guiding evidence-based coverage standards by payers.

The Practice Guideline is a timely resource as the United States is currently experiencing an opioid epidemic. According to the National Institute on Drug Abuse (NIDA), 2.1 million Americans live with pain reliever opioid addiction disease, while 467,000 Americans live with heroin opioid addiction disease. Overdose deaths are now comparable to the number of deaths caused by motor vehicle crashes, and the societal costs of opioid misuse is estimated to be above $55 billion per year.

Medications are both clinical and cost-effective interventions. While the effectiveness of medications has been researched and documented, their utilization is low and coverage varies dramatically. Less than 30% of treatment programs offer medications and less than half of eligible patients in those programs receive medications.

According to Dr. Jeffrey Goldsmith, OPPA member and ASAM President, “Opioid addiction is a chronic, life-threatening disease with significant medical, emotional, criminal justice and societal costs. This guideline is the first to address all the available medications to treat opioid addiction. It will help save lives.”

ASAM worked with Treatment Research Institute (TRI) to develop the Practice Guideline using the RAND/UCLA Appropriateness Method (RAM), a consensus process that combines scientific evidence with clinical knowledge. A Guideline Committee, made up of experts from multiple disciplines, including addiction medicine, psychiatry, obstetrics/gynecology and internal medicine, participated in the consensus process and helped write the guideline. Dr. Kyle Kampman chaired the Guideline Committee and served as TRI’s Principal Investigator. “The Practice Guideline is the most current document of its kind combining review of existing guidelines, current literature and a systematic process for developing practice recommendations.”

The National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use can be accessed HERE, on ASAM’s website

Download the full press release 



Printer-Friendly Version